XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENT OF INCOME - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]        
Sales $ 13,154 $ 10,929 $ 35,183 $ 30,570
Costs, Expenses and Other        
Cost of sales 3,450 3,013 9,752 8,589
Selling, general and administrative 2,336 2,060 6,804 6,336
Research and development 2,445 3,349 9,177 7,609
Restructuring costs 107 113 487 265
Other (income) expense, net (450) (312) (1,007) (637)
Total Costs, Expenses and Other 7,888 8,223 25,213 22,162
Income from Continuing Operations Before Taxes 5,266 2,706 9,970 8,408
Taxes on Income from Continuing Operations 695 380 1,436 1,271
Net Income from Continuing Operations 4,571 2,326 8,534 7,137
Less: Net Income Attributable to Noncontrolling Interests 4 2 9 1
Net Income from Continuing Operations Attributable to Merck & Co., Inc. 4,567 2,324 8,525 7,136
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests 0 617 766 2,025
Net Income Attributable to Merck & Co. Inc. $ 4,567 $ 2,941 $ 9,291 $ 9,161
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders:        
Income from Continuing Operations (in dollars per share) $ 1.81 $ 0.92 $ 3.37 $ 2.82
Income from Discontinued Operations (in dollars per share) 0 0.24 0.30 0.80
Net Income (in dollars per share) 1.81 1.16 3.67 3.62
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:        
Income from Continuing Operations (in dollars per share) 1.80 0.92 3.36 2.81
Income from Discontinued Operations (in dollars per share) 0 0.24 0.30 0.80
Net Income (in dollars per share) $ 1.80 $ 1.16 $ 3.66 $ 3.61